HUMA (Humacyte Inc) Gross Margin

Corporate emblem and logo of Humacyte Inc (HUMA)

Humacyte, Inc. (HUMA) independently produces bioengineered tissues while sourcing raw materials from external partners. The gross margin indicator provided by GURU.Markets recorded the metric at -623.00. Outsourcing logistics and testing to contractors allows the company to focus on research and development. The business is currently transitioning from the research stage to the mass commercial production of innovative HAV vessels.

Humacyte Corp (HUMA): Return on Gross Profit from 07/04/2022 to 11/19/2026

Financial and market metric breakdowns for Humacyte Inc (HUMA)

- price and consensus price forecast:
- business market valuation indicators:
Summary company analysis:Humacyte (HUMA)
Flagship merchandise of Humacyte

The assessment of Humacyte, Inc. (HUMA) margin of safety is based on gross margin, which determines the profit share after deducting direct production costs, reflecting the efficiency of cost management. By analyzing gross margin dynamics, an investor can identify profitability risks driven by technological complexities in scaling the production of biosynthetic tissues and delays in regulatory product approval.